A Study of 1592U89 in HIV-Infected Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002388|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Abacavir sulfate||Phase 1|
Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All patients receive 12 weeks of monotherapy during the initial 12-week treatment phase.
On completion of the treatment phase, patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||48 participants|
|Official Title:||A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002388
|United States, Illinois|
|Evanston Hosp / Clinical Pharmacology Unit|
|Evanston, Illinois, United States, 60201|
|United States, Massachusetts|
|Fenway Community Health Ctr / Research Dept|
|Boston, Massachusetts, United States, 02115|
|United States, New York|
|Albany Med College / Albany Med Ctr Hosp|
|Albany, New York, United States, 12208|